Baxter BioScience, Vaccine Research and Development, Orth an der Donau, Austria.
J Infect Dis. 2012 Jan 1;205(1):28-34. doi: 10.1093/infdis/jir711. Epub 2011 Nov 16.
A Vero cell-derived whole-virus H5N1 influenza vaccine has been shown to induce neutralizing antibodies directed against the hemagglutinin (HA) protein of diverse H5N1 strains in animal studies and clinical trials. However, neuraminidase-inhibiting (NAi) antibodies can reduce viral spread and may be of particular importance in the event of an H5N1 pandemic, where immunity due to HA antibodies is likely absent in the general population. Here we demonstrate the effective induction of NAi antibody titers after H5N1 vaccination in humans. In contrast to the immune response directed toward HA, a single vaccine dose induced a strong NAi response that was not significantly boosted by a second dose, most probably due to priming by previous vaccination or infection with seasonal influenza viruses. After 2 immunizations, seroconversion rates based on antibody titers against HA and NA were similar, indicating the induction of equally strong immune responses against both proteins by this H5N1 vaccine.
一种基于vero 细胞的全病毒 H5N1 流感疫苗在动物研究和临床试验中已被证明可诱导针对不同 H5N1 毒株血凝素（HA）蛋白的中和抗体。然而，神经氨酸酶抑制剂（NAi）抗体可以减少病毒传播，在 H5N1 大流行的情况下可能尤为重要，因为在普通人群中，由于 HA 抗体产生的免疫可能不存在。在这里，我们证明了在人类中接种 H5N1 疫苗后可有效诱导 NAi 抗体滴度。与针对 HA 的免疫反应相反，单次疫苗剂量可诱导强烈的 NAi 反应，而第二剂疫苗接种并未显著增强该反应，这很可能是由于先前接种疫苗或感染季节性流感病毒而产生了启动作用。经过 2 次免疫接种，基于针对 HA 和 NA 的抗体滴度的血清转化率相似，表明该 H5N1 疫苗可诱导针对这两种蛋白的同样强烈的免疫反应。
